Compare State Street SPDR S&P Biotech ETF (XBI) vs State Street Technology Select Sector SPDR ETF (XLK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR S&P Biotech ETF vs State Street Technology Select Sector SPDR ETF — how do they compare? State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B), while State Street Technology Select Sector SPDR ETF trades at $198.78 (market cap $132.55B). The key difference: State Street Technology Select Sector SPDR ETF is far larger — about 13.1× State Street SPDR S&P Biotech ETF's market cap, and State Street Technology Select Sector SPDR ETF is trading nearer its 52-week high, State Street SPDR S&P Biotech ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold State Street SPDR S&P Biotech ETF for 38 Days and State Street Technology Select Sector SPDR ETF for 50 Days on average.
| XBI | XLK | |
|---|---|---|
Market Cap | $10.11B | $132.55B |
Volume | 12,903,266 | 9,063,135 |
Sector | Broad Market / Factor | Sector/Thematic |
52-Week High | $169.55 | $202.00 |
52-Week Low | $104.99 | $127.49 |
Typical Hold Time | 38 Days | 50 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
XBI trades at $153.75, up 2.34% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts like the Merck-Moderna cancer vaccine breakthrough.
Outlook remains mixed with 100% analyst hold rating contrasting with bullish news catalysts. Key risks include high volatility, sector-specific regulatory pressures, and expense ratios higher than broader healthcare ETFs. The current technical setup near resistance requires monitoring for breakout confirmation.
XLK, the Technology Select Sector SPDR ETF, trades at $198.78, down 1.3% over the past day amid broader tech sector pressure. The technical outlook remains bullish based on moving averages, with neutral oscillators suggesting consolidation near the pivot point of $199. Recent news highlights AI-driven momentum in software stocks and ETF concentration concerns, while a future dividend of $0.22 is scheduled for September 2026.
The ETF's outlook is supported by strong AI investment themes and large-cap tech earnings resilience, but risks include interest rate sensitivity and high concentration in semiconductor holdings. Analyst sentiment is mixed, with some favoring alternative tech ETFs for better diversification. Key resistance lies at $201, with support at $196.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →About State Street Technology Select Sector SPDR ETF
XLK tracks the Technology Select Sector Index, providing targeted exposure to the largest and most influential technology companies within the S&P 500. It is a highly concentrated, liquid vehicle focused on software, semiconductors, and hardware leaders, serving as the primary benchmark for U.S. large-cap technology performance.
Read more on XLK →
